Android app on Google Play

Par Pharmaceutical (PRX) Hugs Buyout Price as it Could See Higher Bids

July 16, 2012 11:55 AM EDT Send to a Friend
Get Alerts PRX Hot Sheet
Price: $49.98 --0%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 20 | Down: 9 | New: 24
Trade PRX Now!
Join SI Premium – FREE
Shares of Par Pharmaceutical Companies Inc. (NYSE: PRX) are trading right at its takeover bid with no merger/arbitrage spread as speculators see other bidders stepping up the plate.

This morning, private equity firm TPG agreed to acquire the company for $50 per share in cash.

Analysts at UBS said the deal at 7x-8x EBITDA appears very reasonable and notes similar deals have gotten done at more than 10x. The firm wouldn't be surprised to see a strategic bidder step in at the 8x-9x EBITDA range. Illustrating their confidence in a new bid, UBS raised their price target on Par to $58.

In addition to a higher bid from a strategic buyer, analysts at Barclays see additional bids from financial buyers.

Shares of PRX last traded at $49.99, up 36.66 percent.




You May Also Be Interested In


Related Categories

Analyst Comments, Mergers and Acquisitions, Rumors, Trader Talk

Related Entities

UBS, Barclays

Add Your Comment